340B Discount Drug Program: Inflation Reduction Act, Reimbursement Challenges, Contract Pharmacy Restrictions, and More

The Inflation Reduction Act requires manufacturers to negotiate drug prices with Medicare and pay rebates to Medicare when they increase the price of drugs faster than inflation. Meanwhile, federal courts continue to consider the legality of drug manufacturer policies restricting access to 340B pricing for drugs dispensed through contract pharmacies.

Also, a growing number of states have proposed or enacted legislation hampering health plans and pharmacy benefit managers (PBMs) with respect to reimbursement rates for 340B drugs. A significant number of states have passed legislation that prohibits PBMs from applying different reimbursement policies on claims for 340B drugs relative to non-340B drugs. Other states are considering similar measures.

Listen as our expert panel provides updates on recent judicial and legislative action related to the 340B program and the potential impact of a new administration. The panel will also offer best practices for compliance. 

I.            Inflation Reduction Act and its impact on 340B program

II.           Manufacturer restrictions on contract pharmacies

III.         Reimbursement challenges and state action

IV.         Potential impact of a new administration

V.          Best practices for navigating 340B in light of recent activity

The panel will review these and other key issues:

• How does the Inflation Reduction Act impact the 340B drug program? How may this be affected by the new administration?
• What impact will the recent state legislative activity have on the 340B drug program?
• What do the recent developments mean for future contract pharmacy arrangements?